Drugs / ENCENICLINE
Trials 14
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT01984736 | Jun 2013 → Dec 2014 | — | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT01984723 | Jun 2013 → Feb 2014 | impaired renal function disease | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00766363 | Oct 2008 → Mar 2009 | Alzheimer disease | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT01556763 | Apr → Aug 2008 | schizoaffective disorder, schizophrenia | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02246075 | Jul 2015 → Oct 2016 | Alzheimer disease | FORUM Pharmaceuticals Inc | Withdrawn | No outcome recorded |
| Phase 2 | NCT01764243 | Nov 2012 → Jun 2015 | Alzheimer disease | Tanabe Pharma Corporation | Completed | No outcome recorded |
| Phase 2 | NCT01480232 | Dec 2011 → Sep 2015 | nicotine dependence | A. Eden Evins | Terminated | No outcome recorded |
| Phase 37 trials | ||||||
| Phase 3 | NCT02327182 | Dec 2014 → Sep 2015 | Alzheimer disease | Tanabe Pharma Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT02004392 | Jun 2014 → Aug 2017 | Alzheimer disease | FORUM Pharmaceuticals Inc | Terminated | No outcome recorded |
| Phase 3 | NCT01969123 | Oct 2013 → Jan 2017 | Alzheimer disease | FORUM Pharmaceuticals Inc | Terminated | No outcome recorded |
| Phase 3 | NCT01969136 | Oct 2013 → Jan 2017 | Alzheimer disease | FORUM Pharmaceuticals Inc | Terminated | No outcome recorded |
| Phase 3 | NCT01714713 | Jun 2013 → Oct 2015 | schizophrenia | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 3 | NCT01716975 | Oct 2012 → Feb 2016 | schizophrenia | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 3 | NCT01714661 | Oct 2012 → Dec 2015 | schizophrenia | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
| Comparator or background therapy3 trials | ||||||
| Phase 1 | NCT01487135 Comparator | Dec 2011 → Sep 2013 | — | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 2 | NCT01073228 Comparator | Apr 2010 → Nov 2011 | Alzheimer disease | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 2 | NCT00968851 Comparator | Dec 2009 → Jan 2011 | schizophrenia | FORUM Pharmaceuticals Inc | Completed | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 18 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ENCENICLINE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2151572 ↗ |
| Known as | Enceniclina | ChEMBL registry synonym — accepted as the source's own label CHEMBL2151572 ↗ |
| Known as | ENCENICLINE HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2151572 ↗ |
| Known as | EVP-6124 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01714661 ↗ |
| Known as | EVP-6124 HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2151572 ↗ |
| Known as | MT-4666 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01764243 ↗ |
| Action | Activate | “Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist” CHEMBL2151572 ↗1“Alpha-7 Nicotinic Acetylcholine Receptor Agonist” NCT00766363 ↗ |
| Modality | Small molecule | — CHEMBL2151572 ↗ |
| Route | Oral | “Study drug will be supplied as capsules and will be orally administered once daily” NCT00766363 ↗ |
| Target | CHRNA7 | “Neuronal acetylcholine receptor protein alpha-7 subunit partial agonist” CHEMBL2151572 ↗ |